Clovis Oncology Inc. (CLVS)

5.41
NASDAQ : Health Technology
Prev Close 5.71
Day Low/High 5.41 / 5.86
52 Wk Low/High 4.98 / 34.63
Avg Volume 3.17M
Exchange NASDAQ
Shares Outstanding 54.66M
Market Cap 312.09M
EPS -7.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

CLVS: Insiders Vs. Shorts

CLVS: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and Clovis Oncology Inc is one of the most shorted stocks of the Russell 3000, based on 7.37 "days to cover" versus the median component at 5.30. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

First Week Of April 2020 Options Trading For Clovis Oncology (CLVS)

First Week Of April 2020 Options Trading For Clovis Oncology (CLVS)

Investors in Clovis Oncology Inc saw new options become available this week, for the April 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Clovis Oncology Announces Pricing Of $250 Million Of Convertible Senior Notes

Clovis Oncology Announces Pricing Of $250 Million Of Convertible Senior Notes

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the pricing of $250 million aggregate principal amount of its 4.

Clovis Oncology To Offer $225 Million Of Convertible Senior Notes

Clovis Oncology To Offer $225 Million Of Convertible Senior Notes

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that, subject to market and other conditions, it intends to offer $225 million aggregate principal amount of its convertible senior notes due 2024 (the "notes") in a private placement to qualified...

Clovis Oncology Announces Second Quarter 2019 Operating Results

Clovis Oncology Announces Second Quarter 2019 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2019, and provided an update on Clovis' clinical development programs and regulatory and commercial outlook for the second half of 2019.

First Week Of September 20th Options Trading For Clovis Oncology (CLVS)

First Week Of September 20th Options Trading For Clovis Oncology (CLVS)

Investors in Clovis Oncology Inc saw new options become available this week, for the September 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CLVS options chain for the new September 20th contracts and identified one put and one call contract of particular interest.

Clovis Oncology Is Now Oversold (CLVS)

Clovis Oncology Is Now Oversold (CLVS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Notable Thursday Option Activity: CLVS, NR, CWH

Notable Thursday Option Activity: CLVS, NR, CWH

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Clovis Oncology Inc , where a total volume of 16,765 contracts has been traded thus far today, a contract volume which is representative of approximately 1.7 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 78.7% of CLVS's average daily trading volume over the past month, of 2.1 million shares.

Clovis Oncology To Announce Second Quarter 2019 Financial Results And Host Webcast Conference Call On August 1

Clovis Oncology To Announce Second Quarter 2019 Financial Results And Host Webcast Conference Call On August 1

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2019 financial results on Thursday, August 1, 2019, before the open of the U.

First Week Of CLVS August 16th Options Trading

First Week Of CLVS August 16th Options Trading

Investors in Clovis Oncology Inc saw new options begin trading this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CLVS options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

Change Is in the Air

It's not giddy yet, but we are certainly converting more and more former bears by the day.

Clovis Oncology Enters Oversold Territory (CLVS)

Clovis Oncology Enters Oversold Territory (CLVS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Clovis Oncology Names Ginger L. Graham As New Board Of Directors Chair

Clovis Oncology Names Ginger L. Graham As New Board Of Directors Chair

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the appointment of Ginger L.

Expanded Rubraca® (Rucaparib) Data From Clovis Oncology's ARIEL3 And TRITON2 Trials In Ovarian And Prostate Cancers To Be Presented At 2019 ASCO Annual Meeting

Expanded Rubraca® (Rucaparib) Data From Clovis Oncology's ARIEL3 And TRITON2 Trials In Ovarian And Prostate Cancers To Be Presented At 2019 ASCO Annual Meeting

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced multiple datasets being presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2019.

Clovis Oncology Presents Patient-Centered Outcomes Data From Phase 3 ARIEL3 Study For Rubraca®▼ In Advanced Ovarian Cancer

Clovis Oncology Presents Patient-Centered Outcomes Data From Phase 3 ARIEL3 Study For Rubraca®▼ In Advanced Ovarian Cancer

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced data demonstrating that patients with recurrent ovarian cancer who received Rubraca in the Phase 3 ARIEL3 study had longer periods of quality-adjusted time without clinically relevant symptoms as...

Clovis Oncology Enters Oversold Territory (CLVS)

Clovis Oncology Enters Oversold Territory (CLVS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Clovis Oncology Announces Presentations At 2019 ASCO Annual Meeting

Clovis Oncology Announces Presentations At 2019 ASCO Annual Meeting

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that four abstracts featuring data for Rubraca ® (rucaparib) and ongoing studies in multiple tumor types will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking...

Clovis Oncology Announces First Quarter 2019 Operating Results

Clovis Oncology Announces First Quarter 2019 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2019, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for the rest of the year.

Clovis Oncology To Present At The Bank Of America Merrill Lynch Healthcare Conference 2019

Clovis Oncology To Present At The Bank Of America Merrill Lynch Healthcare Conference 2019

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.

Clovis Oncology Enters Into Non-Dilutive Clinical Trial Financing With TPG Sixth Street Partners For Up To $175 Million

Clovis Oncology Enters Into Non-Dilutive Clinical Trial Financing With TPG Sixth Street Partners For Up To $175 Million

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that it has entered into an agreement for up to $175 million in non-dilutive clinical trial financing with certain affiliates of TPG Sixth Street Partners to reimburse Clovis' costs and expenses related...

Clovis Oncology To Announce First Quarter 2019 Financial Results And Host Webcast Conference Call On May 7

Clovis Oncology To Announce First Quarter 2019 Financial Results And Host Webcast Conference Call On May 7

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2019 financial results on Tuesday, May 7, 2019, before the open of the U.

Clovis Oncology Announces Interim Results From Rubraca® (rucaparib) Phase 2 Study In Advanced Pancreatic Cancer And Nonclinical Data In Multiple Solid Tumor Types For Rucaparib And Lucitanib Presented At AACR 2019

Clovis Oncology Announces Interim Results From Rubraca® (rucaparib) Phase 2 Study In Advanced Pancreatic Cancer And Nonclinical Data In Multiple Solid Tumor Types For Rucaparib And Lucitanib Presented At AACR 2019

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced multiple presentations at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, March 29 - April 3, 2019.

Clovis Oncology Announces Presentations At 2019 AACR Annual Meeting

Clovis Oncology Announces Presentations At 2019 AACR Annual Meeting

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that six abstracts highlighting progress in the Rubraca clinical development and lucitanib preclinical research programs will be presented at the 2019 American Association for Cancer Research (AACR)...

Clovis Oncology To Highlight Rubraca® (rucaparib) Data From Post-Hoc ARIEL3 Analyses At SGO 2019 Congress

Clovis Oncology To Highlight Rubraca® (rucaparib) Data From Post-Hoc ARIEL3 Analyses At SGO 2019 Congress

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that data from post hoc exploratory analyses from the ARIEL3 Phase 3 clinical study of Rubraca will be presented during oral plenary and poster sessions at the Society of Gynecologic Oncology 2019...

Clovis Oncology To Present At The Barclays Global Healthcare Conference

Clovis Oncology To Present At The Barclays Global Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.

ARIEL3 Trial Fact Sheet

ARIEL3 Trial Fact Sheet

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca ® (rucaparib) is now available by prescription in Germany as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian...

3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks

3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks

Quick takes on fourth-quarter results from these 3 biotech names.

TheStreet Quant Rating: D- (Sell)